+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using CD55 mouse mAb against Raji (1) and K562 (2) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of K562 cells using CD55 mouse mAb (green) and negative control (red).    

  
  

CD55 antibody targets CD55 (Decay-Accelerating Factor, DAF), a glycosylphosphatidylinositol (GPI)-anchored membrane protein that regulates complement activation. CD55 protects host cells from complement-mediated damage by binding to C3 convertases, accelerating their decay, and preventing excessive formation of membrane attack complexes (MACs). It is widely expressed on blood cells, endothelial cells, and epithelial tissues. CD55 antibodies are critical tools in studying complement regulation, immune evasion mechanisms in cancers or pathogens, and autoimmune disorders like paroxysmal nocturnal hemoglobinuria (PNH), where GPI-anchor deficiencies lead to CD55 loss.

These antibodies are used in flow cytometry, immunohistochemistry, and functional assays to assess CD55 expression and its role in disease pathogenesis. Therapeutic CD55-targeting antibodies are explored to modulate complement activity—either blocking CD55 to enhance complement-dependent cytotoxicity in cancer or enhancing its function to suppress inflammation. Additionally, pathogens (e.g., enteroviruses) exploit CD55 as a receptor, making its antibodies valuable in virology research. Commercially available clones (e.g., BRIC216. IH4) recognize specific epitopes within the four short consensus repeat (SCR) domains of CD55. enabling diverse research and diagnostic applications.